Budemet400 mcg+12 mcg

Budemet is an inhaled combination of a corticosteroid and a long-acting beta2-agonist (LABA) used for the long-term, regular (maintenance) treatment of certain chronic airway diseases. It is not a rescue medicine for sudden breathing difficulty.

Established / Approved Uses

• Asthma (maintenance treatment): Indicated for regular twice-daily maintenance treatment of asthma in patients (age range depends on the specific approved product/strength, generally from 6 years of age and above) whose asthma is not adequately controlled with a long-term asthma-control medicine such as an inhaled corticosteroid alone, or whose disease severity clearly warrants initiation of combination therapy.
• Chronic Obstructive Pulmonary Disease (COPD): Indicated for the long-term, twice-daily maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema, and for reducing exacerbations of COPD in adults.

Important Limitation

Budemet is not indicated for the relief of acute bronchospasm or acute asthma/COPD symptoms. A separate fast-acting (rescue) inhaler should be used for sudden shortness of breath, and patients should carry one at all times, unless a specific product/regimen has been separately labeled and prescribed by a physician for combined maintenance-and-reliever use. Do not use Budemet as a substitute for oral or inhaled corticosteroids that a patient is being weaned from.

Budesonide + Formoterol Fumarate Dihydrate is a fixed-dose combination product. Each dose combines:

• Budesonide - an inhaled corticosteroid (ICS)
• Formoterol Fumarate Dihydrate - a long-acting beta2-adrenergic agonist (LABA)

In Bangladesh, Budesonide + Formoterol Fumarate Dihydrate is available as a dry powder inhaler (DPI) in strengths such as 100 mcg/6 mcg, 200 mcg/6 mcg, and 400 mcg/12 mcg (budesonide/formoterol per dose), and as a pressurized metered-dose inhaler (MDI) in strengths such as 80 mcg/4.5 mcg and 160 mcg/4.5 mcg per actuation. The exact strengths and device type available may vary by brand.

Budemet combines two medicines that work together to control chronic airway inflammation and keep the airways open. Budesonide reduces inflammation and swelling in the airways over time, while formoterol fumarate dihydrate relaxes the muscles around the airways, allowing air to move more freely. Used together and taken regularly, they help prevent asthma and COPD symptoms such as wheezing, chest tightness, shortness of breath, and cough, and help reduce the frequency of flare-ups (exacerbations).

Budemet is delivered directly to the lungs by inhalation, which allows it to act locally at lower doses than an equivalent oral medicine, with reduced (though not absent) risk of body-wide (systemic) side effects.

Budesonide + Formoterol Fumarate Dihydrate acts through the combined, complementary mechanisms of its two components.

Budesonide (Inhaled Corticosteroid)

Budesonide is a glucocorticosteroid with strong local anti-inflammatory activity in the airways. It reduces the production and release of inflammatory mediators, decreases airway hyperresponsiveness, and reduces mucosal edema and mucus secretion. These effects reduce the frequency and severity of asthma/COPD symptoms and exacerbations, though the full anti-inflammatory benefit may take days to weeks to become fully apparent.

Formoterol Fumarate Dihydrate (LABA)

Formoterol is a selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle, producing bronchodilation. It has a relatively rapid onset of action (within minutes) and a long duration of effect (approximately 12 hours), which supports its role in twice-daily maintenance dosing.

When combined, the corticosteroid component addresses the underlying airway inflammation while the LABA component provides sustained bronchodilation, together improving lung function and symptom control more effectively than either agent alone in appropriately selected patients.

Budemet is for oral inhalation only and must not be swallowed as a tablet or injected. Read and follow the device-specific patient instructions supplied with the inhaler, as technique differs between metered-dose inhalers and dry powder inhalers. Correct inhaler technique is essential for the medicine to reach the lungs effectively; a physician or pharmacist can demonstrate proper technique. Always rinse the mouth with water after use and spit it out. Keep the inhaler clean and dry, and track the dose counter (if present) to know when a refill is needed.

Before using Budemet, tell the physician about all other medicines being used, including the following clinically significant interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): may significantly increase systemic budesonide exposure and the risk of corticosteroid-related side effects; concurrent use should generally be avoided or requires close monitoring.
• Other beta-adrenergic agonists or stimulant drugs (e.g., other bronchodilators, decongestants, stimulant medicines): may add to formoterol's cardiovascular effects (increased heart rate, tremor); use with caution.
• Beta-blockers (including cardioselective agents and eye drops): may reduce the effectiveness of formoterol and can, in some patients, cause severe bronchospasm; use only if clearly necessary and with caution, particularly in patients with airway disease.
• Diuretics (non-potassium-sparing) such as loop or thiazide diuretics: formoterol may worsen ECG changes and potassium-lowering effects of diuretics; monitor potassium levels if used together.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: may potentiate the cardiovascular effects of formoterol; use with caution, particularly within 2 weeks of stopping an MAOI.
• Drugs that prolong the QT interval: may increase the risk of cardiac arrhythmia when combined with formoterol's cardiac stimulant effects.

Side effects of Budemet may arise from either the budesonide (corticosteroid) or formoterol (LABA) component.

Common

• Oral or throat candidiasis (thrush), hoarseness, throat irritation
• Headache
• Nasopharyngitis, upper respiratory tract infection, sinusitis
• Tremor, palpitations, nervousness
• Nausea, stomach discomfort
• Back pain, muscle cramps

Less Common but Clinically Important

• Paradoxical bronchospasm (worsening of wheeze immediately after use) - see Precautions and Warnings
• Cardiovascular effects: fast or irregular heartbeat, chest discomfort, changes in blood pressure
• Signs of systemic corticosteroid effect with long-term/high-dose use (e.g., easy bruising, weight gain, mood changes)
• Hyperglycemia (raised blood sugar) or hypokalemia (lowered potassium), particularly at higher doses
• Signs of allergic reaction: rash, swelling of the face/throat, difficulty breathing (seek urgent care)

Report any severe, persistent, or worsening symptoms to a physician promptly.

Pregnancy: There are no adequate and well-controlled studies of Budemet in pregnant women. As with other asthma/COPD medicines, Budemet should be used during pregnancy only if the potential benefit to the mother (including maintaining adequate control of asthma/COPD, since poorly controlled disease itself carries risk to the pregnancy) justifies the potential risk to the fetus. Use only if clearly needed, and only under medical supervision.

Lactation: Budesonide is known to be present in human breast milk in small amounts; it is not established whether formoterol passes into breast milk. A decision to continue or discontinue breastfeeding, or to continue or discontinue Budemet, should be made by weighing the benefit of breastfeeding against the mother's clinical need for Budemet, in consultation with a physician.

• Not for acute symptom relief: Budemet does not act fast enough to relieve sudden bronchospasm; a separate fast-acting rescue inhaler is needed for acute symptoms in most regimens (unless a physician has specifically prescribed a labeled combined maintenance-and-reliever regimen for a particular product).
• Do not stop abruptly: Discontinuing or reducing Budemet suddenly can lead to worsening of symptoms; dose should be tapered or adjusted only under medical supervision.
• Oropharyngeal candidiasis (oral thrush): Rinse the mouth with water and spit after each use to reduce this risk; treat with antifungal therapy if it occurs, without necessarily stopping treatment, per physician advice.
• Immunosuppression and infection risk: Corticosteroid effects may increase susceptibility to infections and mask their signs. Use with caution in patients with active or latent tuberculosis, untreated fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Caution is advised with exposure to chickenpox or measles in patients who have not had these infections.
• Paradoxical bronchospasm: Rarely, inhaled medicines can cause immediate wheezing or worsening of breathing after use. If this occurs, stop Budemet and seek prompt medical attention; alternative therapy may be needed.
• Cardiovascular effects: The formoterol component can produce measurable effects on heart rate, blood pressure, and ECG (e.g., QT interval). Use with caution in patients with cardiovascular disease, arrhythmias, hypertension, or convulsive disorders, and in those especially sensitive to sympathomimetic amines.
• Systemic corticosteroid effects: With long-term use, especially at higher doses, effects such as adrenal suppression, reduced bone mineral density, cataracts, glaucoma, and slowed growth velocity in children may occur. Use the lowest effective dose for the shortest necessary duration and monitor as clinically indicated.
• Hypokalemia and hyperglycemia: Beta-agonist therapy, particularly at high doses, can lower blood potassium and raise blood glucose; use caution in patients with diabetes or those on medicines affecting potassium.
• Correct inhaler technique is essential for the medicine to work; incorrect technique can significantly reduce lung deposition and effectiveness.

Overdose of Budemet may cause exaggerated effects of its components, particularly from formoterol: symptoms such as chest pain, rapid or irregular heartbeat, tremor, nervousness, headache, nausea, muscle cramps, low blood potassium, high blood sugar, and, rarely, seizures. Overdose of the budesonide component with chronic excessive use may increase the risk of systemic corticosteroid effects.

If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home. Cardiac monitoring and supportive care are generally required; a physician will determine whether specific treatment, such as a cardioselective beta-blocker, is appropriate, weighing the risk of bronchospasm.

Store at room temperature (below 30°C), away from direct light, heat, and moisture. Do not puncture, break, or burn the inhaler canister or capsules, and avoid storing near open flame or in a car on a hot day. Keep the mouthpiece clean and dry, and keep out of reach and sight of children.

Renal impairment: No specific dose adjustment of Budemet has been established as necessary in renal impairment; however, systemic corticosteroid effects should be monitored, as with any patient.

Hepatic impairment: Because budesonide is metabolized in the liver, patients with significant hepatic impairment may have increased systemic exposure to budesonide; use with caution and monitor for corticosteroid-related side effects.

Elderly: No overall differences in safety or effectiveness have been established between elderly and younger adult patients, but age-related cardiovascular disease may warrant additional caution with the formoterol component.

Pregnancy and lactation: See Pregnancy and Lactation section above.

Pediatric use: See Pediatric Uses section below.

Budemet is intended for long-term, regular maintenance use in chronic asthma or COPD, not for short courses. The duration of treatment is determined by the prescribing physician based on ongoing disease control, and therapy is typically continued indefinitely as part of a step-wise asthma/COPD management plan, with periodic review (e.g., every 3-6 months) to consider stepping down therapy once control is achieved, or stepping up if control is inadequate. Do not discontinue treatment on your own even if symptoms improve, without medical guidance.

Inhaled Corticosteroid (ICS); Long-Acting Beta2-Adrenergic Agonist (LABA); Combination Anti-Asthmatic/Anti-COPD Agent

Budesonide + Formoterol Fumarate Dihydrate works through two complementary actions: budesonide, a corticosteroid, suppresses airway inflammation by reducing the activity of inflammatory cells and mediators in the lungs, decreasing airway swelling, mucus production, and hyperresponsiveness. Formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist, binds to beta2-receptors on airway smooth muscle, activating a signaling cascade that relaxes the muscle and widens (dilates) the airways for approximately 12 hours per dose. Together, these actions reduce airway inflammation and maintain open airways, improving airflow and reducing the frequency of asthma/COPD symptoms and exacerbations.

C

The approved pediatric age range for Budemet depends on the specific product strength and formulation, and is determined by the prescribing physician:

• Asthma: Certain lower-strength formulations of Budemet are approved for maintenance asthma treatment in children from around 6 years of age; higher strengths are generally reserved for adolescents 12 years and above and adults. Safety and efficacy in children younger than the approved age for a given strength have not been established, and Budemet should not be used in these younger children unless specifically directed by a pediatrician.
• COPD: Budemet is not indicated for COPD in children, as COPD is a disease of adults.
• Children using inhaled corticosteroid-containing therapy long-term should have their growth monitored periodically by their physician, as orally inhaled corticosteroids may cause a reduction in growth velocity.